Inivata Overview
- Founded
-
2014
- Status
-
Acquired/Merged
- Employees
-
85
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$399M
Inivata General Information
Description
Developer of medical tests designed to detect cancer using liquid biopsies. The company's platform focuses on harnessing the potential of circulating tumor DNA (ctDNA) analysis, monitor response and detect relapse, enabling clinicians to make informed treatment decisions with respect to the treatment of cancer patients.
Contact Information
Website
www.inivata.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Diagnostic Equipment
Parent Company
Primary Office
- Glenn Berge Building
- Babraham Research Campus, Babraham
- Cambridge CB22 3FH
- England, United Kingdom
+44 01223 000000
Inivata Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 18-Jun-2021 | $399M | 00000 | 00000 | Completed | Generating Revenue |
| 6. Secondary Transaction - Private | 15-Mar-2021 | 00000 | Completed | Generating Revenue | ||
| 5. Later Stage VC (Series C) | 04-Feb-2021 | 000.00 | 00000 | 00000 | Completed | Generating Revenue |
| 4. Later Stage VC | 03-Jun-2020 | 000.00 | 00000 | 00000 | Completed | Generating Revenue |
| 3. Later Stage VC (Series B) | 28-Mar-2019 | 000.00 | 00000 | 000.00 | Completed | Generating Revenue |
| 2. Early Stage VC (Series A) | 26-Jan-2016 | $45.6M | $52.2M | 0000 | Completed | Generating Revenue |
| 1. Early Stage VC | 23-Sep-2014 | $6.55M | $6.55M | 000 | Completed | Startup |
Inivata Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C2 Preferred | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 0.000 | ||
| Series C2 Preferred | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 0.000 | ||
| Series C1 | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 0.000 | ||
| Series C1 | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 0.000 | ||
| Series B | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00.000 | ||
| Series B | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 0.000 | ||
| Series A | 16,591,575 | $0.000014 | 7% | $2.59 | $2.59 | $2.59 | 25.34% | |
| Preference | 4,000,000 | $0.000014 | 5% | $1.36 | $1.36 | $1.36 | 6.11% |
Inivata Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of medical tests designed to detect cancer using liquid biopsies. The company's platform focuses on harnessing
Diagnostic Equipment
Cambridge, United Kingdom
85
As of 2021
00000
0000
0000-00-00
000000&0
00000
000000
ore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui offi
0000000000 000000000
Abingdon, United Kingdom
000
As of 0000
00000
0000
0000-00-00
000000&0
00000
000000
esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in
0000000000 000000000
Cambridge, United Kingdom
0
As of 0000
000.00
0.000
0000-00-00
000000&0
000.00
Add Comparison
Inivata Competitors (52)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Oxford Immunotec | Formerly VC-backed | Abingdon, United Kingdom | 000 | 00000 | 000000&0 | 00000 |
| 0000000 | Formerly VC-backed | Cambridge, United Kingdom | 0 | 000.00 | 000000&0 | 000.00 |
| 0000000 0000000000 | Venture Capital-Backed | Beverly, MA | 00 | 00.00 | 0000000000 0 | 00.00 |
| 00000000000 | Venture Capital-Backed | Birmingham, AL | 00 | 00.000 | 0000000000 0 | 00.000 |
| 00000000 | Pending Transaction (M&A) | Irvine, CA | 000 | 000.00 | 000000000 | 000.00 |
Inivata Patents
Inivata Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202212094-D0 | Method of detecting cancer dna in a sample | Pending | 19-Aug-2022 | ||
| EP-4013894-A1 | Method for altering therapy of advanced non-small cell lung cancer patients based on analysis of ctdna | Pending | 13-Aug-2019 | 0000000000 | |
| US-20220325356-A1 | Method for altering therapy of advanced non-small cell lung cancer patients based on analysis of ctdna | Pending | 13-Aug-2019 | 0000000000 | |
| EP-3931356-A1 | Method for quantifying the amount of a target sequence in a nucleic acid sample | Pending | 28-Feb-2019 | 0000000000 | |
| US-20190112645-A1 | Method for measuring mutational load | Active | 21-Dec-2018 | C12Q1/6827 |
Inivata Executive Team (21)
Inivata Board Members (12)
| Name | Representing | Role | Since |
|---|---|---|---|
| Douglas VanOort | NeoGenomics Laboratories | Board Member | 000 0000 |
| Jeffrey Buchalter | Self | Non-Executive Chairman | 000 0000 |
| Peter Wrighton-Smith Ph.D | Self | Board Member | 000 0000 |
Inivata Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Inivata Former Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Cambridge Innovation Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Cancer Research Horizons | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Farallon Capital Management | Hedge Fund | Minority | 000 0000 | 000000 0 | |
| Future Planet Capital | Growth/Expansion | Minority | 000 0000 | 000000 0 | |
| IP Group | Venture Capital | Minority | 000 0000 | 000000 0 |